{"name":"Chengdu Brilliant Pharmaceutical Co., Ltd.","slug":"chengdu-brilliant-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BT-KTM-I","genericName":"BT-KTM-I","slug":"bt-ktm-i","indication":"Acute heart failure","status":"phase_3"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Ketanest®S","genericName":"Ketanest®S","slug":"ketanests","indication":"Induction and maintenance of general anesthesia","status":"phase_3"}]}],"pipeline":[{"name":"BT-KTM-I","genericName":"BT-KTM-I","slug":"bt-ktm-i","phase":"phase_3","mechanism":"BT-KTM-I is a small molecule that targets the PDE3 enzyme.","indications":["Acute heart failure"],"catalyst":""},{"name":"Ketanest®S","genericName":"Ketanest®S","slug":"ketanests","phase":"phase_3","mechanism":"Ketanest®S is a rapid-acting anesthetic that blocks NMDA receptors in the central nervous system to produce dissociative anesthesia and analgesia.","indications":["Induction and maintenance of general anesthesia","Procedural sedation and analgesia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOOERHRlpUVWJZQnhXMzRfVmZXMmtGcFJyNG5IS0piTVJkQ0FKS1d1NWJ5ZnotVkNSY1UwQ2x1ZjVlLV9QSXZZSG1mVXNmOGJBbXdPMVlwWXlfQlNpeHhZbG5IRzZPbGdYTldQTHpJakZnbjdqWUszSnh6Q1BXWVhST1phdGhfOFJvN25peTFQUjJQWmRYb1FRR05lV2xxb2RJZXc?oc=5","date":"2021-12-06","type":"trial","source":"globaldata.com","summary":"Contract Small Molecule API Manufacturing Industry by the Numbers – 2021 Edition - globaldata.com","headline":"Contract Small Molecule API Manufacturing Industry by the Numbers – 2021 Edition","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}